Expertise in
15
conditions

Adrian J. Thrasher

Great Ormond Street, 
London, ENG, GB 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
15
conditions
Great Ormond Street, 
London, ENG, GB 
OverviewLocationsClinical Research

Overview

Adrian Thrasher practices in London, United Kingdom. Mr. Thrasher is highly rated in 15 conditions, according to our data. His top areas of expertise are Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency (SCID), X-Linked Severe Combined Immunodeficiency, Bone Marrow Transplant, and Splenectomy.

His clinical research consists of co-authoring 259 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Great Ormond Street, London, ENG, United Kingdom
Other Locations
72 Huntley Street, WC1E 6BT, London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 with Low Dose Targeted Busulfan Conditioning
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 with Low Dose Targeted Busulfan Conditioning
Enrollment Status: Recruiting
Publish Date: January 06, 2025
Intervention Type: Biological
Study Drug: Autologous CD34-Positive G2SCID Vector-Transduced Peripheral Blood Cells
Study Phase: Phase 1/Phase 2
Long-term Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product
Long-term Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product
Enrollment Status: Active_not_recruiting
Publish Date: February 20, 2025
Intervention Type: Genetic
A Phase 3 Study of Lenti-D Drug Product After Myeloablative Conditioning Using Busulfan and Fludarabine in Subjects ≤17 Years of Age With Cerebral Adrenoleukodystrophy (CALD)
A Phase 3 Study of Lenti-D Drug Product After Myeloablative Conditioning Using Busulfan and Fludarabine in Subjects ≤17 Years of Age With Cerebral Adrenoleukodystrophy (CALD)
Enrollment Status: Completed
Publish Date: May 24, 2024
Intervention Type: Genetic
Study Drug: Elivaldogene Autotemcel
Study Phase: Phase 3
A Phase 2/3 Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)
A Phase 2/3 Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)
Enrollment Status: Completed
Publish Date: April 25, 2022
Intervention Type: Genetic
Study Phase: Phase 2/Phase 3
Phase I/II, Historical Controlled, Open-label, Non-randomised, Single-centre Trial to Assess the Safety and Efficacy of EF1αS-ADA Lentiviral Vector Mediated Gene Modification of Autologous CD34+ Cells From ADA-deficient Individuals
Phase I/II, Historical Controlled, Open-label, Non-randomised, Single-centre Trial to Assess the Safety and Efficacy of EF1αS-ADA Lentiviral Vector Mediated Gene Modification of Autologous CD34+ Cells From ADA-deficient Individuals
Enrollment Status: Completed
Publish Date: September 16, 2021
Intervention Type: Genetic, Drug, Other
Study Phase: Phase 1/Phase 2
Phase I/II Clinical Trial of Haematopoietic Stem Cell Gene Therapy for the Wiskott-Aldrich Syndrome
Phase I/II Clinical Trial of Haematopoietic Stem Cell Gene Therapy for the Wiskott-Aldrich Syndrome
Enrollment Status: Completed
Publish Date: June 03, 2021
Intervention Type: Genetic
Study Phase: Phase 1/Phase 2
Long Term Safety Follow up of Patients Enrolled in the Phase I/II Clinical Trial of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome (GTG002-07 and GTG003-08).
Long Term Safety Follow up of Patients Enrolled in the Phase I/II Clinical Trial of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome (GTG002-07 and GTG003-08).
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2021
Intervention Type: Genetic
Study Drug: Autologous CD34-Positive WASP Lentiviral Vector-Transduced Cells
Study Phase: Phase 1/Phase 2
Phase I/II Clinical Trial of Haematopoietic Stem Cell Gene Therapy for the Wiskott-Aldrich Syndrome
Phase I/II Clinical Trial of Haematopoietic Stem Cell Gene Therapy for the Wiskott-Aldrich Syndrome
Enrollment Status: Completed
Publish Date: May 22, 2018
Intervention Type: Genetic
Study Phase: Phase 1/Phase 2
View 7 Less Clinical Trials

259 Total Publications

Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency.
Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency.
Journal: The New England journal of medicine
Published: October 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Thrasher's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 7 Advanced Conditions
View All 37 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile